 |
|
| Blog results | Results 1 - 10 of about 5,167 for imatinib mesylate. (0.25 seconds) |
| Sorted by relevance Sort by date |
| Related Blogs: | Boycott Novartis - http://novartisboycott.org/ | |
| 8 Oct 2008 Novartis to further explore potential of imatinib mesylate in PAH in An early proof-of-concept study presented today shows promising results for imatinib mesyla. Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 2 Feb 2010 by jenna Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia. Clin Ther. 2009 Nov;31(11):2565-2569. Authors: Campione E, Diluvio L, Paterṇ EJ, Di Marcantonio D, Francesconi A, Terrinoni A, Orlandi A, ... HIV ATLAS - http://www.hivatlas.org/ |
| 33 minutes ago by nothingmandates The guidance states that Sutent is recommended for reimbursement as a treatment opportunity for patients with advanced GIST after murrain progression on or xenophobia to imatinib mesylate, and who have on the agenda c trick an Eastern ... nothingmandates - http://nothingmandates.ilyoor.com/ |
| 4 Feb 2010 by M L Gleevec is in a clinical study: Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate, NCT00038675. The goal of this clinical research study is to see if Gleevec, known as imatinib mesylate (STI571), ... Cancer Treatment - http://cancertreatments.typepad.com/cancer_treatment/ |
| 20 Feb 2008 Manufacturing and dissolution of tablet formulations containing more than 80% of imatinib mesylate based on the total weight of the tablet were manufactured and tested. IP.com Prior Art Database - http://www.priorartdatabase.com/ |
| 10 Jan 2010 The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid... Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r... [ More results from Clinical Trials Updates During the Last 7 Days ] |
| 5 Jan 2010 by Peter Huber Imatinib Mesylate was provided by SUGEN Inc. South San Francisco, CA. To achieve clinically relevant doses [26,27], Imatinib were formulated in standard mouse chow at 0.5 mg/g resulting in a dosage of 40 mg/kg/d. Imatinib (Gleevec) is ... Radiation Oncology - Latest Articles - http://www.ro-journal.com/ |
| 14 Dec 2009 by Cortes, Baccarani, Guilhot, Druker, Branford,... Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase ... Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/ [ More results from Journal of Clinical Oncology Current Issue ] |
| 22 Jan 2010 by rob SUMMARY BACKGROUND: Imatinib mesylate [tyrosine kinase (TK) inhibitor] is a novel medication in the treatment of chronic myelogenous leukaemia (CML). TK is also essential in hypothalamo-pituitary-adrenal (HPA) axis. ... CMLHope.Com - http://cmlhope.com/ [ More results from CMLHope.Com ] |
| 14 Dec 2009 by Wen, PY, Yung, WKA, Lamborn, KR, Norden,... The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas. Patients were stratified into benign ... Neuro-Oncology current issue - http://neuro-oncology.dukejournals.org/ [ More results from Neuro-Oncology current issue ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
